Skip to Content

Symfi Lo Approval History

FDA Approved: Yes (First approved February 5, 2018)
Brand name: Symfi Lo
Generic name: efavirenz, lamivudine and tenofovir disoproxil fumarate
Dosage form: Tablets
Company: Mylan Pharmaceuticals Inc.
Treatment for: HIV Infection

Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) is a three-drug combination of a non-nucleoside reverse transcriptase inhibitor (efavirenz), and two nucleo(t)side reverse transcriptase inhibitors (lamivudine and tenofovir disoproxil fumarate) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

Development History and FDA Approval Process for Symfi Lo

DateArticle
Mar  2, 2018Approval Mylan to Introduce Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) as a New Cost-Saving HIV Combination Treatment in the U.S.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide